INVZ vs. DNA

Last updated Jun 3, 2026

INVZ (Innoviz Technologies Ltd.) and DNA (Ginkgo Bioworks Holdings, Inc.) are both stocks. INVZ operates in Auto Parts (Consumer Cyclical), while DNA operates in Biotechnology (Healthcare). Over the past 5 years, INVZ returned -40.42%/yr vs -52.72%/yr for DNA. At a 0.39 correlation, their price movements are largely independent.

Performance

INVZ vs. DNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Innoviz Technologies Ltd. (INVZ) and Ginkgo Bioworks Holdings, Inc. (DNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, INVZ achieves a -8.29% return, which is significantly lower than DNA's 12.27% return.

INVZ

• 1D: -3.85%
• 1M: 16.58%
• YTD: -8.29%
• 6M: -36.90%
• 1Y: -11.13%
• 3Y*: -36.39%
• 5Y*: -40.42%
• 10Y*: —

DNA

• 1D: 2.08%
• 1M: -3.81%
• YTD: 12.27%
• 6M: 8.61%
• 1Y: 30.86%
• 3Y*: -47.59%
• 5Y*: -52.72%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

INVZ vs. DNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
INVZ Innoviz Technologies Ltd.	-8.29%	-49.22%	-33.60%	-35.62%	-38.01%	-31.53%
DNA Ginkgo Bioworks Holdings, Inc.	12.27%	-15.38%	-85.47%	0.00%	-79.66%	-17.89%

Correlation

The correlation between INVZ and DNA is 0.33, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.33
Correlation (3Y) Calculated over the trailing 3-year period	0.38
Correlation (5Y) Calculated over the trailing 5-year period	0.40
Correlation (All Time) Calculated using the full available price history since Apr 20, 2021	0.39

Fundamentals

Market Cap INVZ : $168.62M DNA : $555.73M
EPS INVZ : -$0.39 DNA : -$5.40
PS Ratio INVZ : 3.62 DNA : 4.32
PB Ratio INVZ : 2.83 DNA : 1.25
Total Revenue (TTM) INVZ : $44.83M DNA : $121.84M
Gross Profit (TTM) INVZ : $4.34M DNA : $99.27M
EBITDA (TTM) INVZ : -$73.94M DNA : -$218.90M

Return for Risk

INVZ vs. DNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

INVZ

INVZ Risk / Return Rank: 37
INVZ Sharpe Ratio Rank: 36
INVZ Sortino Ratio Rank: 42
INVZ Omega Ratio Rank: 40
INVZ Calmar Ratio Rank: 34
INVZ Martin Ratio Rank: 35

DNA

DNA Risk / Return Rank: 53
DNA Sharpe Ratio Rank: 51
DNA Sortino Ratio Rank: 56
DNA Omega Ratio Rank: 55
DNA Calmar Ratio Rank: 52
DNA Martin Ratio Rank: 50

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

INVZ vs. DNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Innoviz Technologies Ltd. (INVZ) and Ginkgo Bioworks Holdings, Inc. (DNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	INVZ	DNA	Difference
Sharpe ratio Return per unit of total volatility	-0.12	0.31	-0.44
Sortino ratio Return per unit of downside risk	0.54	1.14	-0.60
Omega ratio Gain probability vs. loss probability	1.06	1.14	-0.09
Calmar ratio Return relative to maximum drawdown	-0.19	0.52	-0.70
Martin ratio Return relative to average drawdown	-0.30	0.90	-1.20
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

INVZ vs. DNA - Sharpe Ratio Comparison

The current INVZ Sharpe Ratio is -0.12, which is lower than the DNA Sharpe Ratio of 0.31. The chart below compares the historical Sharpe Ratios of INVZ and DNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	INVZ	DNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.12	0.31	-0.44
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.46	-0.54	+0.09
Sharpe Ratio (All Time) Calculated using the full available price history	-0.44	-0.54	+0.11

Drawdowns

INVZ vs. DNA - Drawdown Comparison

The maximum INVZ drawdown since its inception was -96.06%, roughly equal to the maximum DNA drawdown of -99.10%. Use the drawdown chart below to compare losses from any high point for INVZ and DNA.

Drawdown Indicators

	INVZ	DNA	Difference
Max Drawdown Largest peak-to-trough decline	-96.06%	-99.10%	+3.04%
Max Drawdown (1Y) Largest decline over 1 year	-75.21%	-66.05%	-9.16%
Max Drawdown (3Y) Largest decline over 3 years	-88.12%	-94.72%	+6.60%
Max Drawdown (5Y) Largest decline over 5 years	-95.43%	-99.10%	+3.67%
Current Drawdown Current decline from peak	-93.66%	-98.44%	+4.78%
Average Drawdown Average peak-to-trough decline	-74.81%	-79.64%	+4.83%
Ulcer Index Depth and duration of drawdowns from previous peaks	46.82%	38.15%	+8.67%

Volatility

INVZ vs. DNA - Volatility Comparison

Innoviz Technologies Ltd. (INVZ) has a higher volatility of 32.66% compared to Ginkgo Bioworks Holdings, Inc. (DNA) at 23.46%. This indicates that INVZ's price experiences larger fluctuations and is considered to be riskier than DNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	INVZ	DNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	32.66%	23.46%	+9.20%
Volatility (6M) Calculated over the trailing 6-month period	58.71%	70.34%	-11.63%
Volatility (1Y) Calculated over the trailing 1-year period	92.56%	98.67%	-6.11%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	89.01%	97.66%	-8.65%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	89.02%	96.48%	-7.46%

Dividends

INVZ vs. DNA - Dividend Comparison

Neither INVZ nor DNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both INVZ and DNA in my portfolio?

INVZ and DNA have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, INVZ or DNA?

INVZ has higher volatility (32.66%) compared to DNA (23.46%). In terms of maximum drawdown, INVZ dropped -96.06% vs DNA's -99.10%.

Which has better risk-adjusted returns?

DNA currently has the higher Sharpe Ratio (0.31 vs -0.12), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.